David Sparling, MD, PhD

  • Position: Assistant Professor, Pediatric Diabetes & Endocrinology, Diabetes Research Member

Biography

Dr. Sparling has been interested in the role of adipocytes in inflammation. His initial research focused on the function of gamma secretase in regulating adipocyte/macrophage cross talk, but my current focus has shifted to characterization of a novel adipokine, CRISPLD2, that seems to be regulated in states of adipose cell turnover, with possible regulation of inflammation, and insulin sensitivity.

Furthermore, he's developed a special clinical interest in type 1 diabetes mellitus, and his research focuses both on diagnosis and management of children with type 1 diabetes as the site primary investigator for TrialNet and previously with the Type 1 Diabetes Exchange.

Email

David-Sparling@ouhsc.edu

Additional Websites

Health Education
  • Graduate School
  • Fellowship, Pediatric Endocrinology New York-Presbyterian Morgan Stanley Children's Hospital
    New York City, NY
  • Residency, Pediatrics Columbia University College of Physicians and Surgeons, New York Presbyterian
    New York City, NY
  • PhD, Biochemistry University of Oklahoma Health Sciences Center
    Oklahoma City, OK
  • Doctor of Medicine University of Oklahoma College of Medicine
    Oklahoma City, OK
Research Interests:
  • Adipocyte-mediated inflammation
  • Type 1 diabetes
  • Adipose inflammation
  • Insulin signaling
Publications
  • Inhibition of y-secretase in adipocytes leads to altered IL-6 secretion and adipose inflammation 2020

    9(1):325-334. doi: 10.1080/21623945.2020.1788235. PubMed PMID: 32603641; PubMed Central PMCID: PMC7469479.

  • Weight Loss Results in Increased Expression of Anti-Inflammatory Protein CRISPLD2 in Mouse Adipose Tissue 2019

    2025-2036. doi: 10.1002/oby.22652. PubMed PMID: 31746554; PubMed Central PMCID: PMC6873817.

  • Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study 2019

    104(10):4356-4364. doi: 10.1210/jc.2018-02763. PubMed PMID: 31127824; PubMed Central PMCID: PMC7296129.

  • Macrophage-Derived microRNA-155 Increases in Obesity and Influences Adipocyte Metabolism by Targeting Peroxisome Proliferator-Activated Receptor Gamma 2019

    27(11):1856-1864. doi: 10.1002/oby.22616. Epub 2019 Sep 18. PubMed PMID: 31531958; PubMed Central PMCID: PMC6832842.

  • Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity 2016

    5(2):113-121. doi: 10.1016/j.molmet.2015.11.006. eCollection 2016 Feb. PubMed PMID: 26909319; PubMed Central PMCID: PMC4735659.